Ambrx Biopharma’s Oncology Pipeline Is Underappreciated, Analyst Initiating Coverage Says
Cantor Fitzgerald initiated coverage on Ambrx Biopharma Inc (NASDAQ: AMAM) with an Overweight rating and a
Related Posts
Exchange Titans NYSE And Nasdaq Square Off Over New Listings In Reviving IPO Arena
The New York Stock Exchange and Nasdaq Inc (NASDAQ:NDAQ) are aggressively vying for the choicest new stock listings…
SEALSQ AI-Powered Data Processing Pipelines Can Handle Real-Time Streaming Data From IoT Satellites And Semiconductors, Ensuring Smooth And Continuous Data Flow
SEALSQ Corp (NASDAQ:LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum technology hardware and software products today announced
Oppenheimer Downgrades Block to Perform
Oppenheimer analyst Dominick Gabriele downgrades Block (NYSE:SQ) from Outperform to Perform.